The Quantellect read.As of Nov 19, 2026, 7 active firms cover Ocular Therapeutix Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $14.00 to $30.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $24.00 sits 303% above the current $5.95. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$24.00
+303.4% upside
Average target across 7 active firms as of Nov 19, 2026 vs $5.95 current
Highest Target$30.00
Average Target$24.00
Lowest Target$14.00
Detailed analyst forecasts for OCUL
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate OCUL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OCUL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.43 – $-0.34 · 6 analysts · -5% YoY
Next period, 6 analysts expect Ocular Therapeutix Inc to earn $-0.38 a share (range $-0.43 – $-0.34), versus $-0.40 a year earlier. Full-year consensus is $-1.53, growing to $-1.59 the year after.
REVENUE · NEXT QUARTER
$12.3M
Range $11.0M – $13.3M · 6 analysts · +14% YoY
Revenue is expected to reach $12.3M (range $11.0M – $13.3M), +13.8% year-over-year. Full-year consensus is $50.9M, rising to $91.2M next year.
Top analysts covering Ocular Therapeutix Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OCUL.
#1
Daniil Gataulin
Chardan Capital · Rank #51
Buy
$23.00+286.6% to target
Overall win rate
52%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #54
Buy
No targeton OCUL
Overall win rate
43%
+ Follow
#3
Luca Issi
RBC Capital · Rank #76
Buy
$17.00+185.7% to target
Overall win rate
49%
+ Follow
#4
Serge Belanger
Needham · Rank #129
Buy
$18.00+202.5% to target
Overall win rate
46%
+ Follow
#5
Greg Harrison
Scotiabank · Rank #223
Buy
$20.00+236.1% to target
Overall win rate
38%
+ Follow
OCUL stock forecast FAQ
What is OCUL's average 12-month price target?+
The 7 active firms with a live target average $24.00 for Ocular Therapeutix Inc over the next 12 months, ranging from a $30.00 high to a $14.00 low, as of Nov 19, 2026.
Is OCUL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OCUL?+
The Street-high target is $30.00 (Baird), and the Street-low is $14.00 (UBS). The average of all 7 active-firm targets is $24.00.
How many active Wall Street firms cover OCUL?+
7 active firms have a recognized rating on Ocular Therapeutix Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OCUL?+
Among analysts who currently cover OCUL, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $23.00 target.
What is Ocular Therapeutix Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.43 – $-0.34) across 6 analysts. Full-year EPS is projected at $-1.53, rising to $-1.59 the following year.
How much revenue is Ocular Therapeutix Inc expected to report next quarter?+
Consensus revenue is $12.3M (range $11.0M – $13.3M). Full-year revenue is projected at $50.9M, growing to $91.2M next year.
Have analysts been upgrading or downgrading OCUL lately?+
As of Nov 19, 2026, 7 of 7 active firms rate OCUL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OCUL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.